Drug Profile
MDX 210
Alternative Names: Anti-breast-cancer-Trigger; Anti-ovary-cancer-TriggerLatest Information Update: 22 Feb 2010
Price :
$50
*
At a glance
- Originator IDM S.A.
- Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists; IgG receptor antagonists; Immunostimulants; Neutrophil stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Prostate cancer; Renal cancer
Most Recent Events
- 08 Apr 2005 Suspended - Phase-I for Breast cancer in USA (IV)
- 08 Apr 2005 Suspended - Phase-II for Colorectal cancer in Sweden (IV)
- 08 Apr 2005 Suspended - Phase-II for Prostate cancer in USA (IV)